Pre-market hot trades in US stocks: MicroAlgo up 16.42% in pre-market; Alset up 12.26% in pre-market

Tracking Unusual Activity
2025.09.18 08:17
portai
I'm PortAI, I can summarize articles.

MicroAlgo pre-market up 16.42%; Alset pre-market up 12.26%; 89bio pre-market up 86.14%; Aptevo Therap pre-market up 73.05%; AquaBounty Technology pre-market up 65.79%

Popular Pre-Market Trades in US Stocks

Alset is up 12.26% in pre-market trading. Based on recent key news:

  1. On September 16, Chan Heng Fai Ambrose, CEO and 10% shareholder of Alset Inc., sold 500,000 shares of common stock for a total of $1,336,000. This news attracted market attention, leading to stock price fluctuations.

  2. On September 16, Alset Inc. released relevant documents through the EDGAR system, further confirming the above transaction. This information increased market uncertainty, affecting the stock price.

  3. On September 17, the market's reaction to the above transaction continued to ferment, resulting in a 12.26% increase in Alset Inc.'s stock price in pre-market trading. The market reacted strongly to executive trades, and attention should be paid to subsequent trends.

Top Gainers in Pre-Market Trading in US Stocks

89bio is up 86.14% in pre-market trading. Based on recent important news:

  1. On September 18, Roche announced it would acquire 89bio for $14.50 per share in cash, with a total equity value of approximately $2.4 billion, and the total transaction value could reach up to $3.5 billion. This news significantly boosted 89bio's stock price. Data source: Zhitong Finance.

  2. On September 18, Roche plans to accelerate the development of its experimental weight-loss drug, aiming to surpass companies like Novo Nordisk and Eli Lilly. This move further enhanced market confidence in 89bio. Data source: Jiemian.

  3. On September 18, the board of directors of 89bio unanimously recommended that shareholders accept Roche's acquisition offer, with the transaction expected to be completed in the fourth quarter of 2025. This news stabilized investor expectations. Data source: Roche statement. The biopharmaceutical industry is active in mergers and acquisitions, with significant market fluctuations.

Aptevo Therapeutics is up 73.05% in pre-market trading. Based on recent important news:

  1. On September 16, Aptevo Therapeutics announced that its acute myeloid leukemia (AML) RAINIER trial's Cohort 3 achieved a 100% remission rate, leading to a 57% increase in stock price. The trial tested Aptevo's CD123 x CD3 bispecific antibody mipletamig in combination with venetoclax and azacitidine for newly diagnosed AML patients.

  2. On September 16, Aptevo's trading volume surged, with approximately 34 million shares changing hands, while the three-month average daily trading volume was about 165,000 shares.

  3. On September 17, despite facing challenges in financial performance, Aptevo's positive progress in its oncology pipeline provides potential upside. The biotechnology sector has been active recently.

AquaBounty Technologies is up 65.79% in pre-market trading. Based on recent key news: On September 18th, AquaBounty Technologies released its latest technical analysis report, showing mixed momentum indicator signals. Despite the company's poor valuation, reflected in a negative price-to-earnings ratio and lack of dividends, improvements in operational efficiency and cash flow management are crucial to its financial health. This news triggered a positive market reaction, driving the stock price significantly higher

Source: Tracking Unusual Activity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer